Spectrum Pharmaceuticals Inc. (SPPI) announced after the bell Tuesday that Fusilev sales are now expected to be between $10 million and $15 million for the first quarter, and between $80 million and $90 million for the full year 2013.
Spectrum expects full year 2013 revenues of $160 million to $180 million. The consensus estimate is for revenues of $297.33 million.
Spectrum Pharmaceuticals gapped open dramatically lower Wednesday, but was range-bound throughout the session. Shares finished down by 4.64 at $7.79 on the highest volume of the year. The stock sank to a new low for the year.
For comments and feedback: editorial@rttnews.com